Risk of venous thrombosis for high or low levels of protein S
| . | . | . | OR (95% CI)* . | ||
|---|---|---|---|---|---|
| . | Patients, n (%) . | Controls, n (%) . | Overall . | Overall minus† . | Overall minus‡ . |
| Total | |||||
| Free protein S antigen | |||||
| >97.5th percentile (>139 U/dL) | 88 (4.3) | 83 (2.9 | 1.55 (1.14-2.11) | 1.81 (1.31-2.50 | 5.82 (3.14-10.78) |
| 97.5th-2.5th percentile (53-139 U/dL) | 1937 (94) | 2705 (95) | Reference | Reference | Reference |
| <2.5th percentile (<53 U/dL) | 44 (2.1) | 70 (2.4) | 0.82 (0.56-1.21) | 1.51 (0.82-2.78) | 1.04 (0.54-2.01) |
| Total protein S antigen | |||||
| >97.5th percentile (>146 U/dL) | 42 (2.0) | 72 (2.5) | 0.82 (0.56-1.21) | 1.00 (0.66-1.53) | 1.02 (0.62-1.68) |
| 97.5th-2.5th percentile (68-146 U/dL) | |||||
| <2.5th percentile (<68 U/dL) | 50 (2.4) | 72 (2.5) | 0.92 (0.63-1.33) | 1.34 (0.74-2.44) | 1.49 (0.71-3.11) |
| Unprovoked‡ | |||||
| Free protein S antigen | |||||
| >97.5th percentile (>139 U/dL) | 33 (6) | 83 (2.9) | 1.74 (1.13-2.67) | 1.72 (1.12-2.65) | 1.86 (1.19-2.89) |
| 97.5th-2.5th percentile (53-139 U/dL) | 504 | 2705 (95) | Reference | Reference | Reference |
| <2.5th percentile (<53 U/dL) | 8 (1.5) | 70 (2.4) | 1.77 (0.84-3.71) | 2.31 (1.06-5.05) | 1.80 (0.80-4.01) |
| Total protein S antigen | |||||
| >97.5th percentile (>146 U/dL) | 16 (2.9) | 72 (2.5) | 1.21 (0.70-2.10) | 1.15 (0.66-2.00) | 1.14 (0.65-2.00) |
| 97.5th-2.5th percentile (68-146 U/dL) | 524 (94) | 2766 (95) | Reference | Reference | Reference |
| <2.5th percentile (<68 U/dL) | 19 (3.4) | 72 (2.5) | 1.19 (0.55-2.57) | 1.59 (0.71-3.58) | 1.75 (0.79-3.85) |
| Provoked§ | |||||
| Free protein S antigen | |||||
| >97.5th percentile (>139 U/dL) | 55 (3.8) | 83 (2.9) | 1.61 (1.12-2.30) | 3.62 (2.20-5.96) | |
| 97.5th-2.5th percentile (53-139 U/dL) | 1390 (94) | 2705 (95) | Reference | Reference | Reference |
| <2.5th percentile (<53 U/dL) | 35 (2.4) | 70 (2.4) | 0.69 (0.45-1.05 | 1.17 (0.53-2.58) | 1.08 (0.49-2.39) |
| Total protein S antigen | |||||
| >97.5th percentile (>146 U/dL) | 25 (1.7) | 72 (2.5) | 0.74 (0.47-1.18) | 0.95 (0.56-1.59) | 1.05 (0.60-1.83) |
| 97.5th-2.5th percentile (68-146 U/dL) | 1431 (96) | 2766 (95) | Reference | Reference | Reference |
| <2.5th percentile (<68 U/dL) | 39 (2.6) | 72 (2.5) | 0.78 (0.52-2.43) | 1.14 (0.54-2.53) | 1.26 (0.55-2.91) |
| . | . | . | OR (95% CI)* . | ||
|---|---|---|---|---|---|
| . | Patients, n (%) . | Controls, n (%) . | Overall . | Overall minus† . | Overall minus‡ . |
| Total | |||||
| Free protein S antigen | |||||
| >97.5th percentile (>139 U/dL) | 88 (4.3) | 83 (2.9 | 1.55 (1.14-2.11) | 1.81 (1.31-2.50 | 5.82 (3.14-10.78) |
| 97.5th-2.5th percentile (53-139 U/dL) | 1937 (94) | 2705 (95) | Reference | Reference | Reference |
| <2.5th percentile (<53 U/dL) | 44 (2.1) | 70 (2.4) | 0.82 (0.56-1.21) | 1.51 (0.82-2.78) | 1.04 (0.54-2.01) |
| Total protein S antigen | |||||
| >97.5th percentile (>146 U/dL) | 42 (2.0) | 72 (2.5) | 0.82 (0.56-1.21) | 1.00 (0.66-1.53) | 1.02 (0.62-1.68) |
| 97.5th-2.5th percentile (68-146 U/dL) | |||||
| <2.5th percentile (<68 U/dL) | 50 (2.4) | 72 (2.5) | 0.92 (0.63-1.33) | 1.34 (0.74-2.44) | 1.49 (0.71-3.11) |
| Unprovoked‡ | |||||
| Free protein S antigen | |||||
| >97.5th percentile (>139 U/dL) | 33 (6) | 83 (2.9) | 1.74 (1.13-2.67) | 1.72 (1.12-2.65) | 1.86 (1.19-2.89) |
| 97.5th-2.5th percentile (53-139 U/dL) | 504 | 2705 (95) | Reference | Reference | Reference |
| <2.5th percentile (<53 U/dL) | 8 (1.5) | 70 (2.4) | 1.77 (0.84-3.71) | 2.31 (1.06-5.05) | 1.80 (0.80-4.01) |
| Total protein S antigen | |||||
| >97.5th percentile (>146 U/dL) | 16 (2.9) | 72 (2.5) | 1.21 (0.70-2.10) | 1.15 (0.66-2.00) | 1.14 (0.65-2.00) |
| 97.5th-2.5th percentile (68-146 U/dL) | 524 (94) | 2766 (95) | Reference | Reference | Reference |
| <2.5th percentile (<68 U/dL) | 19 (3.4) | 72 (2.5) | 1.19 (0.55-2.57) | 1.59 (0.71-3.58) | 1.75 (0.79-3.85) |
| Provoked§ | |||||
| Free protein S antigen | |||||
| >97.5th percentile (>139 U/dL) | 55 (3.8) | 83 (2.9) | 1.61 (1.12-2.30) | 3.62 (2.20-5.96) | |
| 97.5th-2.5th percentile (53-139 U/dL) | 1390 (94) | 2705 (95) | Reference | Reference | Reference |
| <2.5th percentile (<53 U/dL) | 35 (2.4) | 70 (2.4) | 0.69 (0.45-1.05 | 1.17 (0.53-2.58) | 1.08 (0.49-2.39) |
| Total protein S antigen | |||||
| >97.5th percentile (>146 U/dL) | 25 (1.7) | 72 (2.5) | 0.74 (0.47-1.18) | 0.95 (0.56-1.59) | 1.05 (0.60-1.83) |
| 97.5th-2.5th percentile (68-146 U/dL) | 1431 (96) | 2766 (95) | Reference | Reference | Reference |
| <2.5th percentile (<68 U/dL) | 39 (2.6) | 72 (2.5) | 0.78 (0.52-2.43) | 1.14 (0.54-2.53) | 1.26 (0.55-2.91) |
Adjusted for age and gender.
Estrogen users or pregnancy/puerperium.
Minus estrogen users or pregnancy/puerperium; control group confined to random digit dialing subjects only.
Provoked venous thrombosis classified as thrombosis due to trauma, plaster cast use, surgery, pregnancy/puerperium, or immobilization, within 3 months prior to the index date, >4 hours of traveling by air, train, bus, or car in the 8 weeks before the index date, estrogen/progestogen use at time of the index date, and diagnosis of malignancy within 5 years.